PTO/SB/08a (01-08)
Approved for use through 97/31/2012, OMB 0651-0031
Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO		
INFORMATION DISCLOSURE		Complete if Known
STATEMENT BY APPLICANT	Application Number	10/578,530
	Filing Date	Feb. 1, 2007
	First Named Inventor	Sergei M. Gryaznov
	Art Unit	1635
	Examiner Name	Jane Zara
(Use as many sheets as necessary)		
	Attorney Docket No: 0	074/002

	US PATENT DOCUMENTS						
Examine Initial *	Cite No	Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Collimns, Lines, Where Relevant Passages or Relevant Figures Appear		

	FOREIGN PATENT DOCUMENTS					
Examiner Initials*			Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines, Where Relevant Passages or RelevantFigures Appear	43
***************************************		AU-2004220556	Sep 23, 2004	Alnylam Pharmaceuticals		
	1	AU-2004271215	Mar 17, 2005	Geron Corp.		
	1	AU-2004320900	Jan 5, 2006	Caltech		
		WO 2004/080406	Sep. 23, 2004	Alnylam Pharmaceuticals		

-		OTHER	R DOCUMENTS NON PATENT LITERATURE DOCUMENTS	
- 1	Examiner	Cite	include name of the author (in CAPITAL LETTERS), title of the erticle (when appropriate), title of the item	72
	Initials*	No 1	(book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s),	
- 1			publisher, city and/or country where published.	
Ť			AGAMI, R., "RNAi and related mechanisms and their potential use for therapy",	
i			Curr. Op. Chem. Biol. 6(6) (2002), pp. 829-34	
			(book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.  AGAMI, R., "RNAi and related mechanisms and their potential use for therapy",	<b>F</b>

**EXAMINER** 

/Jane Zara/

DATE CONSIDERED

02/06/2012